Bellerophon Therapeutics, Inc. (BLPH)

Market Cap	440.38K
Revenue (ttm)	5.64M
Net Income (ttm)	-9.25M
Shares Out	12.23M
EPS (ttm)	-0.83
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	155
Open	0.0350
Previous Close	n/a
Day's Range	0.0350 - 0.0360
52-Week Range	0.0290 - 0.4200
Beta	0.70
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 14, 2024

About Bellerophon Therapeutics

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonar...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 18
• Stock Exchange: OTCMKTS
• Ticker Symbol: BLPH